Background: It is unclear whether treating brain metastasis before starting systemic chemotherapy can improve survival compared with upfront chemotherapy in non-small-cell lung cancer (NSCLC) with asymptomatic cerebral oligo-metastases.
introduction
Brain is one of the common sites of distant metastasis in lung cancer. Approximately 30% of patients with lung cancer develop brain metastasis at some point during their illness and silent brain metastasis was reported to be ∼12%-18% at the time of initial presentation [1, 2] . The prognosis with brain metastasis without treatment is very poor, whereas patients with non-small-cell lung cancer (NSCLC) treated with radiation therapy can survival up to 8 months [3] . Whole brain radiotherapy (WBRT) has long been a mainstay of treatment for brain metastases but limited by longterm side-effects. Stereotactic radiosurgery (SRS) is an alternative and less invasive treatment approach involving delivery of high dose of radiation, which allows for precise tumor targeting while minimizing the irradiation to the adjacent normal tissue [4] .
A randomized phase trial reported that compared with SRS alone, the use of WBRT plus SRS did not improve survival for patients with one to four brain metastases [5] . The American Society of Radiation Oncology guideline resultantly suggests SRS without WBRT for patients with up to four brain metastases in solid cancer irrespective of cranial symptoms [6] . Several studies have reported a high incidence of asymptomatic brain metastasis in NSCLC patients and recommend early magnetic resonance imaging (MRI) screening [7, 8] . The detection of occult brain metastasis with MRI followed by accurate staging work-up, and early treatment can improve survival [7] . Until now, the standard treatment of asymptomatic oligo-brain metastasis, especially in NSCLC, has not been fully investigated. This randomized trial was conducted to examine the exact role of SRS in NSCLC patients with asymptomatic oligo-brain metastases, and whether early treatment with SRS would improve survival compared with upfront chemotherapy alone.
methods study design and participants
This study was a single center, randomized phase III trial (NCT01301560), of patients aged 18 years or older with histological confirmed NSCLC with synchronous brain metastases. All patients had one to four parenchymal brain metastases by contrast-enhanced MRI, each with a maximum diameter of no more than 3 cm with brain edema grade 0-1. None of patients had prior surgical treatment or radiotherapy for brain metastases and leptomeningeal metastases by MRI or cerebrospinal fluid evaluation. Eligible patients had ECOG performance status of 0 or 1 and no symptoms or signs from brain metastases. This study was approved by the institutional review boards of Samsung Medical Center. Written informed consent was obtained from each patient before enrollment. Patients with uncontrolled extra-cranial disease, severe co-morbid illnesses and/or active infections were excluded.
randomization and treatment
Eligible patients were randomized to receive either SRS plus systemic chemotherapy or upfront chemotherapy only. Patients with SRS started palliative chemotherapy within 3 weeks after radiosurgery, and SRS was carried out within 2-3 days after randomization. Patients randomized to the observation arm started upfront chemotherapy within 3 weeks from randomization.
The treatment of SRS involves a single high dose of stereotactically focused radiation. Gamma knife radiosurgery (GKS) is SRS using γ-rays from radioactive cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden). In both groups, first-line chemotherapy was given and upon progression, eligible patients received 3 week cycles of the following intravenous chemotherapy; 60 mg/m 2 Patients who were ineligible for cisplatin treatment received carboplatin instead. The choice of chemotherapy regimen was left to the investigator's discretion. Radiological assessments with brain MRI were completed at baseline and 1 month later and every 3 months thereafter for intracranial disease evaluation and contrast CT at baseline and every 6 weeks for extracranial disease evaluation according to the RECIST 1.1 [9] .
end points
The primary end point of the study was overall survival (OS) calculated from the time of randomization to the date of death. Secondary end points included CNS disease progression-free survival (PFS) defined as the time elapsed between randomization and documented intracranial disease progression or death from any cause, progression to symptomatic brain metastasis and deterioration of neurocognitive function. Progression of brain metastasis included local progression and/or the development of a new metastatic lesion. Brain functional outcome measures consisted of cognitive function and activities of daily living. Cognitive function assessment was carried out using MoCA-K (Korean version of Montreal Cognitive Assessment) [10] and K-MMSE (Korean version of Mini-Mental State Examination) [11, 12] . The activity of daily living was assessed using Barthel Activities of Daily Living (BADL) index [13] and Korean version of Instrumental ADL (K-IADL) [14] . During treatment periods, the four aforementioned tests were assessed at baseline and every 3 months until 12 months.
statistical analysis
Assuming a 1-year survival rate of 35% for the upfront chemotherapy group, the expected 1-year survival rate was 54% in the SRS group, with 80% power to detect a hazard ratio of 1.7 by the two-sided log-rank test with an α level of 0.05. We assumed a 10% non-assessable rate including drop out; therefore, the study required a total accrual goal of 176 (88 per arm) patients. OS and PFS were estimated using by the Kaplan-Meier method and were compared between groups using the log-rank test. The time trend of neurocognitive function tests was estimated by a linear model, and the slopes were compared using the generalized estimating equation method based on the working independence structure [15] . P-values of <0.05 were considered statistically significant, and all P-values reported in this paper are two-sided, using SPSS version 21 software (SPSS Inc., Chicago, IL).
This trial was closed early due to slow recruitment since epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) was approved as first-line treatment in patients with EGFR mutation in Korea since 2012.
results patients
Between June 2008 and January 2013, a total of 106 patients were enrolled. One patient was excluded due to pathological confirmation of SCLC. We randomly assigned 105 patients to receive either SRS followed by chemotherapy or upfront platinum-based chemotherapy (supplementary Figure S1 , available at Annals of Oncology online). Four patients in the SRS arm and five in the upfront chemotherapy arm were excluded because their first-line treatments were EGFR TKIs, crizotinib or singleagent chemotherapy. The clinicopathologic characteristics of all patients are listed in Table 1 . More than 80% of patients had adenocarcinoma histology and never smoked patients represented 39% of all patients. Although the mean number of brain metastases was not significantly different between two groups (P = 0.108), the proportion of patients having two to four brain metastases was slightly lower in the upfront chemotherapy arm (43% versus 63%). Compared with the SRS group, patients receiving upfront chemotherapy treatment showed higher proportion of more than two extracranial metastasis sites (P = 0.026). The mean NSCLC-specific GPA score was 2.28 in the SRS group and 2.33 in the upfront chemotherapy group. There was no significant difference between two treatment groups according to GPA (P = 0.932) [16] . Among 73 of the total 98 patients who were known for EGFR mutation status, activating EGFR mutation was found in 16 (33%) and 15 (30%) patients for the SRS and upfront chemotherapy arms, respectively. Baseline neurocognitive function was assessed, and the mean values of efficacy At the data cut-off point (1 April 2014), the median follow-up duration was 43.0 months (range 0.8-56.2). Among the chemotherapeutic regimens, gemcitabine plus cisplatin/carboplatin was more frequently used in both groups (55%) followed by pemetrexed plus cisplatin. The median OS in the SRS group was 14.6 months (95% CI 9.2-20.0) and 15.3 months (95% CI 7.2-23.4) in the upfront chemotherapy group with a hazard ratio of 1.2 (95% CI 0.77-1.89, P = 0.418) (Figure 1 ). The median PFS of cranial disease was 9.4 months (95% CI 4.2-14.6) for patients treated with GKS followed by chemotherapy compared with 6.6 months (95% CI 2.9-10.3) for those treated with upfront chemotherapy only. There was a favorable trend of intracranial disease PFS for the SRS group (P = 0.248; supplementary Figure S2A , available at Annals of Oncology online), whereas the median PFS of extracranial disease was equally 5.4 months in both groups (P = 0.824; supplementary Figure S2B , available at Annals of Oncology online). We separately analyzed clinical outcomes of intracranial disease, including local brain PFS and new lesion PFS. The median local brain PFS was significantly higher in the SRS group (not reached) compared with that of the upfront chemotherapy group (10.2 months, 95% CI 6.5-13.9; P < 0.001). There was no significant difference with regard to new lesion PFS (11.9 versus 8.7 months, P = 0.247 in the SRS and upfront chemotherapy group, respectively) (supplementary Figure S3 , available at Annals of Oncology online). The overall response rate (ORR) of cranial disease was 57% in the SRS group and 37% in the upfront chemotherapy group (P = 0.011) (supplementary Table S1 , available at Annals of Oncology online). The ORR of extra-cranial disease was similar in both groups (43% in the SRS group versus 40% in the upfront chemotherapy group). Nine (18.4%) patients in the SRS arm and 13 (26.5%) in the upfront chemotherapy arm were progressed with symptomatic brain metastasis. Salvage treatment of cranial disease including another GKS, surgery or WBRT were needed more in the upfront chemotherapy group compared with the SRS group (P = 0.157) (supplementary Figure S4 , available at Annals of Oncology online).
The multivariate analysis revealed that adenocarcinoma histology, high extra-cranial metastases (≥2), high number of brain metastases (≥2) and wild-type EGFR mutation were associated with a worse prognosis (supplementary Table S2 , available at Annals of Oncology online).
neurocognitive function Figure 2 exhibits relatively uniform time trend of four neurocognitive function scores in patients treated with GKS and upfront chemotherapy. The proportion of patients who underwent each neurocognitive function test according to the pre-specified time points were similar between two treatment groups. There were no significant differences in improvement or worsening of MoCA-K (P = 0.9932), K-IADL (P = 0.4252), Barthel ADL scores (P = 0.9657) and K-MMSE (P = 0.3798) between two treatment groups over time.
discussion
To our knowledge, this is the first randomized study to examine the role of SRS followed by systemic chemotherapy compared with upfront chemotherapy in NSCLC patients with asymptomatic oligo-brain metastases. This study did not yield in superior outcome of SRS followed by chemotherapy over upfront chemotherapy alone in terms of OS. Hitherto, surgical resection plus postoperative WBRT and SRS with or without WBRT is the standard recommended treatment for limited brain metastatic lesions [17] . Previous studies demonstrated low intracranial relapse rates without OS improvement with the addition of WBRT to SRS over SRS alone in selected patients with limited metastatic brain lesions [5, 18, 19] . In view of the paucity of confirmatory results and the consequent indefinite guideline for the optimal treatment in NSCLC patients with silent (asymptomatic) oligo-brain metastases, our results contribute and elucidate more defined treatment regimen by substantiating the use of upfront systemic chemotherapy alone without local treatment. Our results are comparable to a previous randomized pilot study, which demonstrated that the response rate and survival outcomes in the primary chemotherapy arm were not statistically different from those in the upfront WBRT followed by the chemotherapy arm (ORR, 28.0% versus 39.1%; OS, 9.1 versus 9.9 months, respectively) [20] . In addition, this randomized, controlled trial study also confirmed the previous retrospective study demonstrating no difference of OS between SRS followed by chemotherapy and upfront chemotherapy in asymptomatic brain metastasis [21] . In the era of targeted therapy, it may be reasonable to consider only targeted therapy in neurologically asymptomatic patients with brain metastases before radiotherapy or radiosurgery administration [17] .
The survival rate in this study was unexpectedly high. When the study was designed in 2008, the OS rate of 35% at 1 year (6-7 months of the median OS) was anticipated by platinum doublet chemotherapy, which was predicated on the available scientific literature at the time [22] . In our study, the 1-year survival rate was 57% in the GKS group and 58% in the observation group, and may be attributed to the relatively homogenous study population with better prognostic factors such as high adenocarcinoma histology (80%) and activated EGFR mutation (30%). This characteristic finding was similar to the proportion reported in a previous study, which detected EGFR mutations in ∼40% of Korean NSCLC patients with adenocarcinoma histology [23] . In addition, introduction of pemetrexed in the treatment of non-squamous cell lung cancer has improved OS and allowed more patients to receive salvage therapy due to low toxicity [24] . Twenty-one (43%) and 17 (35%) patients were treated with pemetrexed as their second-or third-line chemotherapy in the SRS and upfront chemotherapy arms, respectively. Thirtyone (63%) in the GKS arm and 28 (57%) patients in the upfront chemotherapy arm were treated with EGFR TKIs (gefitinib or erlotinib) as subsequent treatment (supplementary Table S3 , available at Annals of Oncology online).
The response rate of cranial disease to upfront chemotherapy was 37% which was consistent with previous studies reporting high response rates [20, 21, 25, 26] . High response rate to upfront chemotherapy in our study may be due to a large proportion of never smokers and EGFR mutation. In contrast, the cranial response to SRS in this study (57%) was relatively lower than we had anticipated. Given the lack of standard criteria for cranial response to SRS, the response we have observed may have been underestimated. Stable lesions evaluated after 1-3 months of SRS can have subsequent responses [27] . If stable lesions can be considered as 'tumor control', reflecting radiographic tumor response of SRS, then the brain lesion control rate, local control rate and new lesion progression free rate at 6 months are 78.2%, 89.6%, and 70.8%, respectively, and the rates at 1 year are 44.1%, 84.6%, and 47.4%, respectively. Furthermore, the wax and wane nature of brain metastatic lesions after SRS along with radiation necrosis may lead to overdiagnosis of progression. Taken together, further research regarding standardization of response criteria for brain metastasis to SRS is warranted. Compared with the upfront original articles Annals of Oncology chemotherapy group, SRS-treated patients were observed with several clinical benefits. There was a trend toward longer CNS PFS, lower symptomatic brain progression rate and lower rate of CNS salvage therapy.
The results of neurocognitive function tests had no significant changes in preservation or deterioration of neurologic functions between two treatment groups. Given that SRS resulted in modest clinical benefit albeit without improved survival, and with no significant neurocognitive deterioration, treatment with SRS may be considered, but warrant further research for its optimal use. This study had several limitations. First, the study was underpowered because of small sample size. Secondly, salvage treatments including SRS, surgery and/or WBRT for cranial disease progression were permitted in both study groups, which may have limited the true treatment effect as determined by improved OS. Thirdly, the number of brain metastases was not evenly distributed between two groups. However, there was no difference in total cumulative brain tumor volume between two groups and the higher number of extracranial metastasis in the upfront chemotherapy group may have compensated for the potential imbalance between two groups. Previous studies suggest low disease volume instead of number of metastatic lesions as predictors for survival benefits [28, 29] .
In conclusion, the OS was not improved by SRS followed by chemotherapy compared with upfront chemotherapy in oligobrain metastases NSCLC patients. Given the small sample size due to early termination, further study with large number of patients should be warranted to confirm the use of upfront chemotherapy alone in the initial management.
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